Japanese study for usefulness of vitamin E in reducing aromatase inhibitor-associated joint symptoms

Japanese study for usefulness of vitamin E in reducing aromatase inhibitor-associated joint symptoms - Japanese study for usefulness of vitamin E in reducing aromatase inhibitor-associated joint symptoms (Juvera trial)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004416

Enrollment

Registered

2010-11-01

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Medication of vitamin E

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal breast cancer patients who are aged 50 and over, received surgery and/or adjuvant chemotherapy and/or postsurgical radiotherapy, and currently taking a aromatase inhibitor as adjuvant hormone therapy Patients who report CTC Grade 2 or 3 arthralgia after initiation of aromatase inhibitor therapy Patients whose written informed consent are available

Exclusion criteria

Exclusion criteria: Patients who are suffering bone or joint disease, such as rheumatoid arthritis, osteoarthritis deformans, frozen shoulder syndrome, severe osteoporosis etc. Previous history of neurological disorder Recurrent breast cancer cases Vitamin E users as supplement Patients who are taking a anticoagulant or are expected surgery

Design outcomes

Primary

Measure	Time frame
Serum concentration of estrogen	—

Secondary

Measure	Time frame
Efficacy for joint symptom, adverse event, serum concentration of vitamin E and IL-6	—

Countries

Japan

Contacts

Public ContactMasujiro Makita

Cancer Institute Hospital Breast Center Breast Oncology

mmakita@jfcr.or.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026